Human Material
A total of 22 patients (12 women, 10 men; mean age, 45.7±3.1 years; age range, 30 to 60 years) with type 2 diabetes mellitus attending the clinic for routine control visits were included in the study; hemoglobin A 1c >7.4% (9.01±0.37%) and fasting plasma glucose, 8.35±0.82% mmol/L. All patients were treated with insulin alone or in combination with metformin. Nondiabetic, age-matched subjects (12 women, 10 men; mean age, 41.6±7.5 years; age range, 25 to 60 years; hemoglobin A 1c , 4.98±0.58%; fasting plasma glucose, 5±0.19 mmol/L) who had not taken any medication known to interfere with platelet aggregation for at least 10 days before the experiment served as the control group. The study protocol was approved by the ethics committee of the Goethe University Hospital (No. E 61/09 geschäfts Nr 86/09) and all the participants gave written informed consent.
Statistics
Data are expressed as the mean±SEM, and statistical evaluation was performed using Student t test for unpaired data, 1-way ANOVA followed by Bonferroni t test, or ANOVA for repeated measures where appropriate. Values of P<0.05 were considered statistically significant.
Reagents and other detailed methods are described in the Online Data Supplement.
Results

Cleavage of Dicer in Diabetic Platelets
Platelets express part of the miRNA processing machinery and while argonaute 2 levels were comparable in healthy and diabetic platelets, Dicer levels were significantly decreased (79±3%) in platelets from diabetic patients ( Figure 1A ). However, in some samples the antibody used picked up a potential degradation product (arrow in Figure 1B ) indicating that Dicer may have been targeted by proteases.
Given that Dicer is a calpain substrate in neurones, 18 we determined whether Dicer can be cleaved by calpain in platelets. When platelets from healthy individuals were incubated with Ca 2+ to activate the Ca 2+ -sensing receptor, the autolytic cleavage of calpain 1 (Capn1 or μ-calpain) occurred together with a slight
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Capn calpain FXIII-A factor XIII-A miRNA microRNA pre-miR precursor miRNA Figure 1 . Calpain-dependent cleavage of Dicer in platelets. A, Dicer and argonaute 2 (Ago2) levels in platelets from healthy (H) and diabetic (D) subjects. B, Dicer, calpain 1 (Capn1) and latent calpain 2 (L.Capn2) levels in platelets from healthy and diabetic subjects. C, Effect of calpain activation with Ca 2+ (5 mmol/L) or Ca 2+ and ionomycin (Iono; 1 μmol/L) on Dicer, Capn1 and Capn2 in platelets from healthy volunteers. Experiments were performed in the presence of solvent and calpeptin (10 μmol/L). D, Effect of acute calpain activation on Dicer levels in platelets from wild-type (WT) and Capn1 −/− mice. Experiments were performed in the presence of solvent and calpeptin. The graphs summarize data from 5 to 8 individuals and 5 mice per group; **P<0.01, ***P<0.001 vs healthy or solvent-treated platelets; ##P<0.01 vs the absence of Ca 2+ and ionomycin.
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but distinct shift in the mobility of Dicer in SDS-PAGE (arrowhead on Figure 1C ). No shift was observed in the presence of the calpain inhibitor, calpeptin. The combination of Ca 2+ and ionomycin was, however, required to activate calpain 2 (Capn2 or m-calpain; decrease in latent levels), which in turn resulted in the further degradation of Dicer and the appearance of a degradation product similar to that detected in platelets from some diabetic individuals (arrow in Figure 1C ). Again cleavage was not observed in the presence of calpeptin. A similar phenomenon could be demonstrated in murine platelets but the antibody used was unable to detect putative-cleaved products. Cleavage was not observed in the presence of calpeptin but was similar in platelets from wild-type and Capn1 −/− mice ( Figure 1D ) indicating that Dicer is predominantly a Capn2 substrate.
We next determined the consequences of acute and prolonged calpain activation on Dicer activity. Let-7 was chosen for this assay as it is an abundant Dicer-regulated platelet miRNA. Acute treatment of washed platelets from healthy individuals with Ca 2+ or Ca 2+ and ionomycin increased the generation of mature let-7 in a calpeptin-dependent manner (Figure 2A ), indicating that calpain-dependent cleavage acutely increases Dicer RNAse III activity. However, more maintained calpain activation in platelets from diabetic subjects could be separated into 2 groups, that is, those in which low levels of Dicer were still detectable; usually demonstrating better insulin sensitivity (homeostasis model assessment-insulin resistance, 4.66±0.54; n=8), and those with no detectable full-length or cleaved Dicer protein (homeostasis model assessment-insulin resistance, 7.65±1.47; n=8). Although the Dicer-containing diabetic human platelets were able to metabolize the pre-miR-substrate to the mature miRNA (cleavage was 25.7±0.2% versus 25.5±4.8% in platelets from healthy and diabetic individuals, respectively), they also gave products of an unexpected size (≈35 nt; Figure 2B ). Platelets from the Dicer-poor group, however, generated significantly less mature miRNA ( Figure 2C ). Thus, although the acute activation of calpain increased Dicer activity, the cleavage of the protein by Capn2 was linked to loss of expression, incomplete pre-miRNA processing and decreased activity.
Consequences of miR-223 Knockout on Platelet Function
Circulating levels of platelet-enriched miRNAs are decreased in diabetes mellitus. 12 We confirmed that miR-142, miR-143, miR-155, and miR-223 were all expressed in platelets from nondiabetic individuals and that levels were reduced in ageand sex-matched diabetic subjects ( Figure 3A) . A similar phenomenon was observed in platelets from 5-month-old diabetic Ins2
Akita mice versus their nondiabetic littermates ( Figure 3B ). Given that platelet miR-223 was downregulated in diabetes mellitus, we studied the consequences of its deletion on platelet function, making use of the available male wild-type (miR-223 y/+ ) and miR-223 knockout (miR-223 y/− ) mice. 19 MiR-223-deletion was not associated with a clear difference in tail bleeding time ( Figure 4A ) but was linked with the enhanced in vivo formation of platelet-neutrophil aggregates ( Figure 4B ). Thrombus formation after FeCl 3 -induced carotid artery injury was also elevated in miR-223 y/− mice ( Figure 4C ); clot formation was accelerated (time to maximum was 3.7±1.0 minutes in wild-type versus 2.5±1.0 minutes in miR-223 y/− mice, n=6 per group; P<0.001) and the overall thrombus size was increased. In the microcirculation, however, embolism was increased in the miR-223 y/− mice, with 3 of 11 wild-type vessels developing emboli compared with 13 of 15 vessels studied in miR-223 y/− mice ( Figure 4D ). Dicer activity in platelets from healthy vs diabetic humans. Assays were performed by incubating synthetic 32 P labeled let-7a precursor miRNA (pre-miR) with platelet protein extracts. MicroRNAs were detected by denaturing PAGE and autoradiography. A, Pre-miR cleavage by lysates prepared from platelets isolated from healthy volunteers stimulated with solvent (S), Ca 2+ (C) or Ca 2+ and ionomycin (CI) in the absence and presence of calpeptin. B, Dicer and calpain 1 (Capn1) levels (top) and cleavage of 32 P labeled let-7a pre-miR (bottom) by protein extracts from platelets from healthy (H) and diabetic (D) subjects. The break in the blot indicates that the samples were nonadjacent lanes on the same gel. C, Cleavage of 32 P labeled let-7a pre-miR by protein extracts from platelets from healthy and Dicer-poor diabetic subjects. The graphs summarize data from 6 to 8 individuals per group; ***P<0.001 vs healthy or solvent-treated platelets; § § §P<0.001 vs the absence of calpeptin. Akita (Akita) littermates. The graphs summarize data from 8 individuals per group or 7 to 9 murine blood samples per group; *P<0.05, **P<0.01 vs healthy/WT platelets.
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The deletion of miR-223 enhanced aggregation in vitro induced by low concentrations of thrombin and collagen ( Figure 5A ), without affecting responses to higher concentrations of either agonist or aggregation induced by fibronectin or the thromboxane analog U46619 (Online Figure IA and IB) . Platelets from miR-223 y/− mice also demonstrated a delayed clot retraction to a low concentration of thrombin (0.1 U/mL; Figure 5B ) but no differences when higher concentrations (0.75 U/mL) were used (data not shown). Although platelet adherence to collagen was not different between the 2 groups, spreading was increased in miR-223 y/− platelets ( Figure 5C ). No significant differences in platelet adherence or spreading on fibronectin, laminin, or vitronectin were observed (Online Figure IC and IE) . The most obvious phenotype of the miR-223 y/− platelets was the spontaneous formation of large aggregates, a phenomenon that was independent of the matrix studied ( Figure 5D ; Online Figure II) . These alterations were similar to those reported previously for streptozotocin-induced diabetes mellitus 17 and comparable changes in platelet function were observed in animals made diabetic with a high-fat diet >20 weeks (Online Figure IIIA) , as well as in mice treated with antagomirs directed against miR-223 (Online Figure IIIB) .
MiR-223 and the Platelet Proteome
Two-dimensional differential in-gel electrophoresis combined with mass spectrometry was used to identify miR-223 targets in murine platelets. A comparison of platelets from wild-type and miR-223 y/− mice revealed marked differences in the expression of functionally relevant platelet proteins (Online Figure IV ; Table I ). Of the proteins identified, 2 were chosen for further functional studies, that is, fermitin family homolog 3 (kindlin-3) and coagulation factor XIII-A (FXIII-A).
The increase in kindlin-3 in miR-223 y/− platelets was confirmed by Western blotting ( Figure 6A ) and was accompanied by an increase in the expression of β1 and α2 integrin, whereas the expression of β3 and α5 integrin were unaffected (Online Figure V) . Comparable changes in kindlin-3, β1, and α2 integrin expression were also detected in platelets from patients with type 2 diabetes mellitus ( Figure 6B ) and in platelets from mice fed a high-fat diet (Online Figure VIA) . Although kindlin-3 was picked up in the proteomic assay it could not be identified as a direct target of miR-223 (Targetscan, miRDB, and miRanda) and it was unaffected by miR-223 antagonism in wild-type mice (Online Figure VIB) . There was also no indication that α2 integrin could be directly regulated by miR-223. Given that kindlin-3 is an integrin-binding protein and that β1 integrin is targeted by miR-223 in endothelial cells 20 we hypothesized that the changes in kindlin-3 may have been secondary to that of y/− (y/−) mice were isolated and aggregation to thrombin and collagen was assessed. B, Thrombin-induced clot retraction in platelet-rich plasma from wild-type and miR-223 y/− mice. C, Adherence and spreading of platelets from wild-type and miR-223 y/− mice on collagen; bar, 10 μm. D, Number and size of aggregates generated by washed platelets from wild-type and miR-223 y/− mice on collagen; bar, 50 μm. The graphs summarize data from 12 to 23 mice per group; *P<0.05, **P<0.01, ***P<0.001 vs wild-type. To determine to what extent the functional defects in miR-223 y/− platelet function could be attributed to alterations in β1 integrin signaling, experiments were performed with the α2β1 antagonist rhodocetin. 21 There was no effect of rhodocetin on the adhesion of miR-223 y/− platelets to collagen (not shown) but it normalized spreading ( Figure 6C ) and prevented aggregate formation ( Figure 6D ). The abnormal platelet spreading and aggregate formation by platelets from diabetic humans was also normalized in the presence of rhodocetin (Online Figure VIII) .
The second protein studied more closely was FXIII-A. The expression of the full-length protein was increased in platelets from miR-223 y/− mice as was that of a band of lower molecular mass (≈55 kDa) recognized by the same antibody ( Figure 7A) . A significant, although less pronounced increase in FXIII-A and the 55 kDa band was also detected in platelets from diabetic versus healthy humans ( Figure 7B ). The altered protein levels were accompanied by an increase in FXIII activity ( Figure 7C) . A seeding sequence (6 base pairs of complementarity) for miR-223 was identified in 3′UTR region of FXIII-A and cotransfecting HEK-293 cells with increasing concentrations of pre-miR-223 and a luciferase construct containing the putative miR-223 binding sequence within the 3′UTR of FXIII-A, resulted in a concentration-dependent decrease in luciferase activity (Online Figure IXA) . No effect of pre-miR-223 was detected when the binding sequence was mutated, indicating that FXIII-A is directly targeted by miR-223. Moreover, miR-223 antagonism in mice over 12 days increased platelet FXIII-A levels (Online Figure VIB) .
FXIII-A is involved in fibrin clot stabilization through fibrin-fibrin cross-linking, 22 and as increased clot stability may delay clot retraction we reassessed clot formation and retraction in miR-223 y/− platelets. Clot retraction was attenuated in platelet-rich plasma from miR-223 y/− mice, and FXIII inhibition with putrescine, 23 normalized responses. A similar effect was detected in samples from diabetic subjects ( Figure 7D ) and comparable results were obtained using tridegin, 24 a second FXIII inhibitor (Online Figure IXB) .
Consequences of In Vivo Calpain Inhibition on Dicer and miR-223 Levels
To demonstrate a direct link between diabetes mellitus, calpain activation, and the proteolysis of Dicer, mice were made diabetic with streptozotocin. Twelve weeks after the induction of diabetes mellitus, platelet Capn2 could not be detected in the latent form ( Figure 8A ) and Dicer levels were effectively decreased. Treating mice with the calpain inhibitor A-705253 for 12 days before euthanization significantly increased platelet Dicer levels in non-diabetic animals and prevented its loss in diabetic mice. In the same animals, the proteins previously found to be upregulated in miR-223 y/− mice, that is, kindlin-3, β1 integrin, and FXIII-A were all increased by diabetes mellitus and largely reversed by calpain inhibition ( Figure 8B ). In the same animals, diabetes mellitus was associated with a decrease in mature miR-223 levels and an increase in pre-miR-223 levels ( Figure 8C) . A-705253 treatment, however, restored levels of both the species toward those detected in non-diabetic, vehicle-treated mice. Clearly, many miRNAs are affected by alterations in platelet Dicer levels, and the diabetes mellitus-associated decrease in miR-143 was also restored by calpain inhibition ( Figure 8D ) and a similar tendency was observed with miR-155 (Online Figure X) . However, miR-451a, which is regulated by Dicerindependent mechanisms, 25, 26 was not attenuated in platelets from streptozotocin-treated mice ( Figure 8E ), diabetic Ins2 Akita mice ( Figure 8F ) or from diabetic human subjects ( Figure 8G ).
Discussion
The results of this investigation indicate that the decrease in platelet miRNA levels detected in diabetic subjects has consequences on platelet protein expression as well as function. Focusing on only 1 platelet-enriched miRNA, that is, miR-223, it was possible to relate changes in miRNA levels with a hyper-reactive and hyper-adhesive phenotype, as well as with altered levels of β1 integrin and FXIII-A. Moreover, altered platelet miRNA expression in diabetes mellitus could be linked to the activation of calpain and the proteolysis of the RNAse III Dicer, eventually resulting in decreased Dicer activity.
That circulating levels of platelet miRNAs are altered in subjects with diabetes mellitus has been clearly demonstrated by others, 12-14 and we were able to confirm those findings by analyzing a subset of miRNAs. To determine the molecular events responsible for the decrease in miRNA levels, we focused on the expression of Dicer and argonaute 2, both of which are donated to platelets by the parent megakaryocyte. Although Dicer was clearly expressed in platelets from healthy individuals, it was almost undetectable in platelets from severely diabetic patients (hemoglobin A 1c , >7.4%). Levels of argonaute 2, however, were comparable in platelets from healthy and diabetic individuals. In some of the samples studied, the antibody used picked up possible Dicer degradation products indicating that the loss of expression may represent protein cleavage. In fact, proteases are assumed to be required for Dicer activation, as the full-length Dicer protein is part of a multimolecular complex and largely inactive. Proteases known to target Dicer include the cell death protease CED-3; that can convert Dicer from an RNase III to a DNase after cleavage of its N-terminal DCR-1 sequence, 27 caspase-3; which can generate 50 kDa C-terminal and 180 kDa N-terminal Dicer fragments that are catalytically inactive, 28 and calpain. 18 The acute activation of the latter protease has been linked to an increase rather than a decrease in Dicer activity. Certainly, the removal of the auto-inhibitory N-terminal domain increases Dicer activity and fragments of 75 and 50 kDa have been reported after the treatment of recombinant Dicer with Capn1, a step that also increases RNAse III activity. 18, 29 In platelets from nondiabetic subjects, the acute activation of calpains resulted 
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in the accelerated processing of premature let-7a, indicating increased dicer activity. In platelets from diabetic subjects, however, the longer term activation of calpains resulted in the depletion of Dicer to such an extent that activity was either altered or markedly attenuated (depending on the degree of insulin insensitivity). Indeed, in a subgroup of diabetic individuals with detectable platelet Dicer levels, mature let-7a was generated together with apparently inappropriately processed miRNA products. Platelets from healthy subjects failed to generate these intermediates; producing only the mature miRNAs, whereas platelets from patients with little or no full-length Dicer failed to process the pre-let-7a used as substrate for the assay. Inappropriate or asymmetrical Dicer processing was previously reported to result in the generation of atypical miRNAs of ≈35 nt 30 and may correspond to pre-miRNA substrates cleaved only once by Dicer, as proposed previously. 31 Whether there are functional consequences of these intermediates on platelet protein expression or function is unknown.
There is currently great interest in the role played by platelet-derived miRNAs for use as biomarkers of disease, 12, 32 but little is known about the consequences of decreased miRNA levels on platelet function. One miRNA, miR-223, was selected for closer study as although its expression increases during megakaryocyte differentiation and it is highly expressed in healthy platelets, 2,30,33 and low levels have been reported to predict platelet reactivity as well as responsiveness to clopidogrel. 8 Moreover, miR-223 was previously shown to affect platelet function 2 and was 1 of only 2 circulating miRNAs inversely associated with the risk of myocardial infarction. 32 We found that in miR-223 y/− mice, thrombus size and embolism were increased in vivo and ex vivo the aggregation elicited by low concentrations of thrombin and collagen was increased. There was also a significant delay in clot retraction and a marked increase in platelet spreading and the formation of platelet aggregates by samples from miR-223 y/− mice. Such changes were highly reminiscent of the phenotype of platelets from diabetic subjects. 34 However, although our results are in agreement with those of others who observed that alterations in miR-223 levels affect platelet function, at least partly by affecting P2Y 12 purinergic receptor expression and activity, 2, 8 other researchers recently failed to see any consequence of the loss of miR-223 on platelet activation. The reason for these conflicting results are unclear but may be related to the concentration of the platelet agonists studied, 35 as the clearest effects in this study were observed using lower agonist concentrations.
Two-dimensional in-gel electrophoresis was used to identify platelet proteins altered in miR-223 y/− mice and of the proteins identified, we concentrated on 2 candidates known to regulate platelet function, that is, kindlin-3 and FXIII-A. These proteins were selected for further study because of their role in the regulation of platelet function and because of the fact that they are not known calpain targets. Both kindlin-3 and FXIII-A were upregulated in platelets lacking miR-223 as well as in platelets from diabetic mice and human individuals. Kindlin-3 is an integrin-binding protein, 36 and its altered expression was paralleled by increased expression of β1 and α2 integrins in platelets from miR-223 y/− mice and diabetic subjects. Although it was regulated in platelets from miR-223 y/− mice, kindlin-3 does not seem to be a direct target of this miRNA because no apparent seeding sequence was detectable and kindlin-3 was unaffected by miR-223 antagonism in wild-type mice. Given that β1 integrin is directly targeted by miR-223, 20 we postulated that an increase in β1 expression may affect the expression or stability of its binding partner. However, the siRNA-mediated downregulation of β1 integrin had no effect on kindlin-3 levels (at least in cultured endothelial cells) suggesting that different, more indirect, mechanisms underlie the effects observed. The increases in α2β1 integrin were, however, functionally relevant as while the adherence of miR-223-deficient mouse platelets and diabetic human platelets to different matrices was not altered, spreading was increased in miR-223-deficient platelets. Also, an α2β1 antagonist was able to prevent the increase in spreading as well as the spontaneous formation of large platelet aggregates in samples from miR-223 y/− mice and diabetic human platelets, indicating that elevated α2β1 integrin signaling contributes to the phenotype observed.
The second protein investigated in more detail was FXIII-A, which makes up half of an inactive transglutaminase tetrameric complex. The FXIII-A subunit contains the active site of the enzyme and is present in large amounts as a homodimer in platelets. 37 Once activated, it cross-links platelet fibrin, making clots mechanically stronger and protecting them against fibrinolysis. 37 Given its role in determining the mechanical stability of the clot, increased FXIII-A levels could account for the larger and apparently stable clots generated after FeCl 3 injury in the carotid artery. We also found that the defective clot retraction observed using platelets from miR-223 y/− mice or diabetic humans was normalized by 2 different FXIII inhibitors. Our observation that FXIII-A levels were increased in platelets from diabetic wild-type mice and human subjects correlates well with reports of increased plasma FXIII levels in subjects with type 2 diabetes mellitus. 38 Until now, there has been no explanation for the increase in FXIII activity in diabetes mellitus but the observation that platelet FXIII-A levels and FXIII activity are directly regulated by miR-223, which declines in diabetic platelets, goes a long way to explaining this phenomenon.
Could the activation of calpain in diabetic megakaryocytes or platelets be responsible for the limited proteolysis and altered activity of Dicer that ultimately leads to altered platelet miRNA levels? To make a link between calpain activity, miRNA levels and the miR-223 targets identified, animals made diabetic with streptozocin were treated with the calpain inhibitor A-705253 for 12 days. Although streptozocin is a model for type 1 rather than type 2 diabetes mellitus, we have previously shown that this model elicits a similar platelet calpain activation as seen in human type 2 diabetes mellitus. 17 Calpain inhibition in vivo restored levels of full-length Dicer to control (and above) at the same time as increasing mature miR-223 and decreasing β1 integrin, kindlin-3 and FXIII-A levels. Although this study focused on miR-223 for functional analyses, it is clear that alterations in Dicer activity would be expected to affect a spectrum of miRNAs and it was possible to demonstrate diabetes induced decreases in miR-143 and miR-155 levels. However, platelet levels of miR-451a, which is known to be regulated by Dicer-independent mechanisms, 25,26 tended to increase in streptozotocin-treated mice; a finding that fits well with a previous report. 39 However, in a genetic model of murine diabetes mellitus or in human platelets, miR-451a was unaffected. Thus, Dicer is a novel substrate of calpain in platelets and the reported improvement in platelet function after calpain inhibition, previously assumed to be the consequence of the direct cleavage of specific platelet proteins, 17 may also be related to the increased expression of platelet proteins whose expression is determined by Dicer-regulated miRNAs. Our study has additional implications given the fact that current miRNA antagonist and mimetic strategies tend to focus on 1 key miRNA altered by a given disease, even though disease is associated with changes in a spectrum of miRNAs.
40 By targeting calpain, particularly when the altered miRNA profile is linked to changes in calpastatin levels or Dicer activity, it may be possible to prevent or reverse changes in several miRNAs or even restore the healthy miRNA profile.
The fact that the acute activation of calpain was required for Dicer activation may imply that long-term calpain inactivation may be detrimental to global miRNA production. This seems unlikely to be the case as although studies assessing changes in miRNA levels as a consequence of calpain inhibition in healthy animals have not been performed, the long-term treatment with A-705253 in vivo is well tolerated and can protect against platelet hyper-reactivity, 17 retinal damage 41 as well as penile nitrergic nerve and dysfunction in diabetic mice. 42 In this study, calpain activation in platelets was clearly demonstrable while there was no evidence of protease activation in hearts or kidneys from the same animals (I. Fleming, unpublished data, 2014). One reason for the apparent lower threshold for calpain activation in platelets than others cells and tissues may be related to the comparatively low platelet expression of the endogenous calpain inhibitor; calpastatin. 43 Whether calpain activation; such as that linked with cardiac ischemia reperfusion injury 44 or myocardial infarction 45 are also linked to an altered tissue miRNA profile subsequent to the cleavage of Dicer remains to be determined. What Is Known?
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• Platelet-derived microRNAs (miRNAs) contribute to the circulating miRNA pool. • Diabetes mellitus is associated with a marked change in the circulating miRNA profile.
• Diabetes mellitus-induced platelet hyper-reactivity is linked to calpain activation.
What New Information Does This Article Contribute?
• miRNA maturation is attenuated in platelets from diabetic humans and mice because of the lack of functional Dicer.
• Dicer is a calpain 2 substrate in human and murine platelets and Dicer cleavage by calpain inhibits Dicer activity.
• Calpain inhibition in vivo prevents the diabetes mellitus-induced decrease in platelet miRNA levels and the increase in target protein levels.
Platelets contain high levels of miRNAs but as they are anucleate they are unable to generate novel primary miRNA transcripts, rather platelet Dicer and Argonaute 2 convert precursor miRNAs donated from the parent megakaryocyte into mature miRNA. Diabetes mellitus is associated with a marked change in the profile of platelet miRNAs but the reasons underlying this effect are unknown. We report that the activation of calpain 2 in diabetic platelets cleaves Dicer and prevents the normal maturation of platelet precursor miRNAs. Taking the decrease in miR-223 as an example, it was possible to show that the increased expression of the miR-223 targets; β1 integrin and factor XIII-A could be linked to changes in platelet function similar to those observed in diabetes mellitus. In vivo calpain inhibition was able to prevent the decrease of a spectrum of Dicer-regulated platelet miRNAs (miR-223, miR-143, and miR-155) without affecting levels of miR-451a, which is regulated by dicer-independent mechanisms. Thus, by targeting calpain in diseases such as diabetes mellitus, it may be possible to prevent or reverse changes in several miR1
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Reagents
Type I collagen and fibronectin were from BD transduction laboratories (Heidelberg, Germany). Vitronectin was from Millipore, calpeptin was from Calbiochem (Darmstadt, Germany) and thrombin from Hemochrom Diagnostica (Essen, Germany). U46619 was from Enzo Life Science (Lörrach, Germany) and the α2β1 blocker; rhodocetin, was kindly provided by Johannes Eble (Frankfurt, Germany). The calpain inhibitor N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethyl-aminomethylphenyl)ethen-1-yl]benzamide (A-705253) was provided by AbbVie Deutschland GmbH & Co. KG (Ludwigshafen, Germany). Laminin, putrescine, 3,3′-dihexyloxacarbo-cyanine iodide (DiOC 6 ) and all other compounds were from Sigma-Aldrich (Steinheim, Germany). Tridegin was from Zedira (Darmstadt, Germany).
The anti-β1 integrin, CD61 FITC, and CD45 PE were obtained from BD Biosciences (Heidelberg, Germany). The antibodies against α2 integrin and α5 integrin were from Millipore (Schwalbach, Germany), anti-FXIIIA was from Acris (Montluçon, France), anti-Dicer from Abcam (Cambridge, UK) and anti-Ago2 was from cell signaling (Frankfurt, Germany). The anti-β3 integrin antibody was from Epitomics (Berlin, Germany) and anti-kindlin-3 was from Abnova (Heidelberg, Germany). The antibodies recognizing β-actin, µ-calpain, and m-calpain were from Sigma-Aldrich (Munich, Germany).
Animals
C57BL/6 mice (6-8 weeks old) were purchased from Charles River (Sulzfeld, Germany). miR-223-deficient mice 1 were kindly provided by Fernando D. Camargo (Harvard University, Cambridge, MA 02138m USA) and heterozygous C57BL/6-Ins2 Akita /J mice were purchased from The Jackson Laboratory (Farmington, CT, USA). Calpain 1 (Capn1) -/-mice, generated by crossing "floxed" Capn1 (Capn1 tm1.1Arte ) mice with animals expressing the Cre-recombinase under the control of the CMV promoter, 2 were bred by the animal facility at the University of Frankfurt. Mice were housed in conditions that conform to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH publication no. 85-23). Both the University Animal Care Committees and the Federal Authorities for Animal Research at the Regierungspräsidium Darmstadt (Hessen, Germany; # F28/21, F28/44 and FU1012) approved the study protocols. Age-, gender-, and strain-matched animals (usually littermates) were used throughout.
Some of the C57BL/6 mice were also treated with either control antagomir (GFP specific) or antagomir directed against miR-223 (both 8 mg/kg, 100 µl; VBC Biotech, Vienna, Austria) three times over 12 days. Diabetes was induced with a single intraperitoneal injection of streptozotocin (STZ; 150 mg/kg) or by feeding animals a high fat diet (58% fat; ssniff, Soest, Germany) for 20 weeks. Animals were considered diabetic when fasting plasma glucose was over 250 mg/dL. In some experiments STZ-treated animals were treated by oral gavage with the calpain inhibitor A-705253 (30 mg/kg/day) for 12 days after 12 weeks untreated diabetes.
Human material
A total of 22 patients (12 women, 10 men; mean age, 45.78±3.12 years; age range, 30 to 60 years) with type 2 diabetes mellitus attending the clinic for routine control visits were included in the study; hemoglobin (Hb)A1c over 7.4% (9.01±0.37%) and fasting plasma glucose, 8.35±0.82 mmol/L. All patients were treated with insulin alone or in combination with metformin. Nondiabetic, age-matched subjects (12 women, 10 men; mean age, 41.6±7.5 years; age range, 25 to 60 years; HbA 1c , 4.98 ±0.58%; fasting plasma glucose, 5±0.19 mmol/L) who had not taken any medication known to interfere with platelet aggregation for at least 10 days before the experiment served as the control group. The study protocol was approved by the ethics committee of the Goethe University Hospital (No. E 61/09 geschäfts Nr 86/09) and all of the participants gave written informed consent.
2D-DIGE analysis
Two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) 3, 4 was performed using the CyDye DIGE Fluors minimal labeling kit (GE Healthcare #28-9345-30, Freiburg, Germany) according to the manufacturer´s instructions, with minor modifications. Briefly, four samples (each representing platelets pooled from 6 mice), from either wild-type or miR-223 -/-mice were solubilized in DIGE labeling buffer (7 mol/L urea, 2 mol/L thiourea, 4 % Chaps and 30 mmol/L Tris/HCl pH 8.6), sonicated for a few seconds on ice and centrifuged (10,000 g, 10 min, 4°C). The protein content of the supernatant was determined using Bradford-Ultra For mass spectrometric protein identification a preparative gel generated using ~200 µg of a mixture of all samples was prepared, fixed in 50% methanol, 10% acetic acid, stained in SYPRO Ruby (Sigma S4942), then destained in 10% methanol, 7% acetic acid and washed in water. The preparative gel was placed on a frame fixed cellophane sheet (GE Healthcare), scanned and matched to the analytical gels in the BVA module of DeCyder 2-D 7.0 software (GE Healthcare). Spots of interest (Student's t-test, p-value < 0.05, average ratio  1.15) were picked by Ettan spot picker (GE Healthcare) into perforated 96 well plates and proteins were identified by mass spectrometry.
In-gel tryptic digests for mass spectrometry
The in-gel digests were performed essentially as described. 5 Briefly, gel pieces in perforated 96-well plates were washed twice in 50% methanol, 50 mmol/L ammonium hydrogen carbonate and then incubated for 30 minutes at 4°C in 5µL 5 ng/µL trypsin in 50 mmol/L ammonium hydrogen carbonate, 10% acetonitrile and 1 mmol/L calcium chloride. Each gel slice was covered by 20 µL of 50 mmol/L ammonium hydrogen carbonate and tryptic digestion was carried out overnight at 37°C. The peptide containing supernatants were collected by centrifugation into a new 96 well plate. The gel pieces were incubated with 50% acetonitrile, 1% formic acid for another 45 minutes to extract remaining peptides. Supernatants were combined and dried in a SpeedVac.
Mass spectrometry
Dried tryptic peptides were dissolved in 15 µL 5% acetonitrile, 0.5% formic acid and analyzed by liquid chromatography/mass spectrometry (LC-MS). Briefly, a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Dreieich, Germany ) was coupled to an Agilent 1200 series nano-HPLC system and tryptic peptides from each 2-D gel spot separated on a column consisting of 10 cm x 75 μm ID fused silica emitter tip filled with 3 μm C18 reversed phase silica (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) using 40 minute gradients of 5% to 50% acetonitrile with 0.1% formic acid, followed by a column wash and re-equilibration for 10 minutes each. Eluted peptides were electrosprayed in positive ion mode and analyzed by a MS method programmed to fragment top ten most abundant precursor ions using dynamic exclusion for 3 minutes with a resolution of 30,000 at 400Th. Single-charged precursor ions were rejected, doubly and higher charged ions were fragmented in the linear ion trap by CID at 35% normalized collision energy. Database searches were performed using Mascot server 2.2 as database search engine. Following parameters were set: 5 ppm deviation on the precursor and 0.8 Da on fragment masses, fixed carbamidomethylation of cysteine, variable oxidation of methionine and trypsin as protease (full tryptic with one missed cleavage allowed). Spectra were matched against Mus musculus reviewed protein database containing 16541 sequences obtained from www.uniprot.org. Database search results were filtered by individual peptide ion score cut-off value calculated by Mascot to indicate identity or extensive homology (P<0.05).
Plasmid construction and reporter gene assays
The 3' UTR of FXIIIA as a reporter gene construct was purchased from Origene (Frankfurt am Main, Germany) and the mutation of the FXIIIA miR-223 seeding sequence was generated using the QuickChange kit (Stratagene, Waldbronn, Germany) with miR-223 mutation primers. The primer sequences used for cloning and mutation were:
Cloning primer
Sequence FXIIIA 3' UTR mutation forward primer 5`-GCTTAAAATAAAGTTAAACGCGTTATATTTGCACGCGTAAG CGG -3` FXIIIA 3' UTR mutation reverse primer 5`-CCGCTTACGCGTGCAAATATAACGCGTTTAACTTTATTTTAA GC -3` For the 3' UTR reporter gene assay, the appropriate plasmids were transfected into HEK293 cells in the presence and absence of pre-miR-223 and pcDNA3.1CMV--gal (Invitrogen, Darmstadt, Germany) for 48 hours.
Reverse transcription and real time PCR (RT-qPCR)
Total RNA from platelets was extracted using a miRNA easy kit (Qiagen, Hilden, Germany) and equal amounts (50 ng) of total RNA was reverse transcribed (Superscript III, Invitrogen, Heidelberg, Germany). mRNA levels were detected using SYBR Green (Absolute QPCR SYBR Green Mix; Thermo Scientific, Hamburg, Germany). To quantify miRNAs, specific stem-loop primers were used for reverse transcription then specific primers, conserved reverse primer and FAM-labeled oligonucleotides (universal probe library probe #13, Roche Diagnostics, Mannheim, Germany) were used for the subsequent real-time qPCR. The relative expression level of miRNA and genes were calculated using the 2 -∆∆Ct method relative to 18S RNA. 
Primer
Platelet isolation
Human platelets: Platelets were obtained by centrifugation (900g, 7 minutes) of platelet-rich plasma, as described. 6 The resulting pellet was washed in Ca 2+ -free HEPES buffer (mmol/L: NaCl, 136; KCl, 2.6; MgCl 2 , 0.93; NaH 2 PO 4 , 3.26; glucose, 5.5; HEPES, 3.7; pH 7.4 at 37°C). Platelet pellets were either resuspended in Ca 2+ -free HEPES buffer to a density of 4x10 8 platelets/mL for Western blotting or to a density of 1x10 7 platelets/mL for the adhesion assay. In some cases, platelet pellets were snap frozen with liquid nitrogen and stored at -80°C until use.
Murine platelets: Mice were anesthetized with isoflurane and blood was collected from the retroorbital plexus into a tube containing 10% acidic citrate dextrose (120 mmol/L sodium citrate, 110 mmol/L glucose, 80 mmol/L citric acid) as anticoagulant. Platelets were prepared from whole blood by differential centrifugation and resuspended in Ca 2+ -free HEPES buffer to a density of 4x10 8 platelets/mL for Western blotting, 1x10 8 platelets/mL for aggregation studies and 1x10 7 platelets/mL for adhesion assays.
For miRNA analyses, high purity platelets were obtained using a hematopoietic progenitor cell depletion kit (STEMCELL, EasySep negative selection, Grenoble, France) according to the manufacturer's protocol.
Platelet aggregation
Aggregation of washed murine platelets (1x10 8 platelets/mL in 250 µL) was measured using an 8-channel aggregometer (PAP8, Mölab, Germany) as described. 
Clot retraction
Platelet-rich plasma (adjusted to 300x10 9 platelets/mL for human platelets and 5x10 8 platelets/mL for murine platelets, 300 μL) obtained by centrifugation of whole blood at 250g for 10 minutes, was stimulated with thrombin (0.1 U/mL) in the presence of CaCl 2 (20 mmol/L) and 10 μL erythrocytes to enhance the contrast of the clot. The clots were allowed to retract for up to 1 hour at 37°C and were photographed at different time points. The extent of retraction was quantified using imageJ software (ImageJ 1.44p, USA).
Bleeding time
Mice were restrained in appropriate restrainer and placed on a heated mat. A 1 mm section of the tail tip was cut, and the tail tip was immediately immersed in sterile saline at 37°C. The bleeding time (i.e, the time between initial flow of blood and its cessation) was recorded. When no blood was observed on the saline after 60-s intervals, bleeding was considered to have ceased. The experiment was stopped after 20 minutes. The mice were monitored for an additional 10 minutes.
Intravital assessment of arteriolar thrombus formation
To assess thrombus formation in vivo, mice were anesthetized by intraperitoneal injection of ketamine and xylazine and placed on a heated mat. The fluorescent dye 3,3' dihexyloxacarbocyanine iodide (DIOC6; Invitrogen, Darmstadt, Germany) was injected into the jugular vein (5 μL of a 100 μmol/L solution/g body weight) to allow visualization of the thrombus. Thereafter, a segment of the right carotid artery was exposed and injury was induced by the topical application of FeCl 3 for 2 minutes (Whatmann paper 1 mm 2 soaked with 0.2 μL of 10% FeCl 3 ) as described. 7 The artery was then rinsed with saline and thrombus formation was monitored for 30 minutes by placing the carotid artery under a fluorescence microscope equipped with a camera (AxioScope, Carl Zeiss, Jena, Germany). Fluorescent images were acquired sequentially (1 image/second) and thrombus size was quantified using AxioVision 4.8.2 imaging software (Carl Zeiss).
To assess thrombus formation in a resistance bed thrombus formation in vivo was assessed in the dorsal skinfold chamber in mice using a light dye injury model. Briefly after surgical preparation of the dorsal skinfold chamber as described previously, 8 the animals fulfilling the criteria for an intact microcirculation (accurate arteriolar blood flow, absence of surgery-related artefacts) underwent carotid artery catheterization for application of the dye. After injection of 4 μL/g of 5% FITC-dextran (150,000 MW) photoactivation was initiated by exposing the vessel to a 100 W mercury lamp (Fluoarc HBO100, Carl Zeiss) using the respective fluorescence filter. Intravital fluorescence microscopy was performed using a Zeiss Axiotech Vario microscope (Zeiss, Göttingen, Germany) and thrombus formation was recorded with a digital camera (AxioCam HSm, Carl Zeiss) in 2-4 arterioles per mouse with at least 40 μm in diameter. Onset of thrombus formation, stability of thrombi (emboli with a diameter larger than half of the vessel diameter) and time to complete thrombotic vessel occlusion resulting in flow cessation were analyzed.
Platelet adhesion and spreading assays
Static adhesion assays were performed as described. 9 Washed human or murine platelets were suspended into platelet buffer containing physiological concentration of 1.8 mmol/L CaCl 2 in the absence or in the presence of the selected inhibitor. Platelet suspensions (1x10 4 platelets/µL in 300 μL) were seeded on plastic slides (µ-Slide 8 well, ibidi, Martinsried, Germany), coated with fibronectin (100 µg/mL), vitronectin (1 μg/mL) collagen (50 µg/mL) or laminin (10 µg/mL) and incubated at 37°C for 30 minutes. Non adherent platelets were washed off and adherent and spread platelets as well as the large platelet aggregates were fixed. Images were captured by a AxioCam MRm on a Cell Observer microscope (Zeiss, Jena, Germany) and analyzed using the imaging software AxioVision 4.8 (Zeiss, Jena, Germany).
Flow cytometry analysis of platelet-leukocyte aggregates
Anticoagulated whole murine blood (100 µL) was incubated for 15 minutes at room temperature in the dark with a phycoerythrin-conjugated anti-mouse CD45 antibody and a FITC-conjugated anti-mouse CD61 antibody or matched mouse IgG isotype controls. Then 1 mL erythrocyte lysis buffer was add to lyse erythrocytes (30 minutes, room temperature). After centrifugation and washing pellets were fixed with formalin (2% vol/vol in PBS) then washed and resuspended in PBS. Samples were then analyzed by flow cytometry (FACS Calibur flow cytometer; BD Biosciences).
FXIII activity assay
Human or murine platelet-rich plasma was incubated with or without the FXIII inhibitor (putrescine, 20 mmol/L or tridegin, 50 µg/mL) for 30 minutes at 37°C. FXIII activity was measured with a microtiter assay using fibrinogen and 5-(biotinamido) pentylamine as substrates, as described.
10,11
Dicer activity assay Washed platelets from healthy or diabetic individuals were isolated as described and incubated with or without Ca 2+ and ionomycin for 30 minutes at 37°C. Thereafter platelets were washed and resuspended in Dicer assay buffer and Dicer activity was assessed using 32 P randomly labeled human pre-let7-3, as described.
12,13
Immunoblotting
Washed human or murine platelets (4x10 8 platelets/mL) were solubilized in SDS sample buffer, separated by SDS-PAGE and subjected to Western blotting. Proteins of interest were visualized by enhanced chemiluminescence using a commercially available kit (Amersham, Freiburg, Germany), as described.
14
Statistics
Data are expressed as the mean  SEM, and statistical evaluation was performed using Student's t test for unpaired data, 1-way analysis of variance (ANOVA) followed by Bonferroni t test, or ANOVA for repeated measures where appropriate. Values of P<0.05 were considered statistically significant. 
